Patients with CML in the lymphoid blastic phase have inferior response to anti‐CD19 CAR T‐cell therapy compared to de novo Ph‐positive B cell acute lymphoblastic leukemia
Mei‐Jing Liu,
Kai‐Wen Tan,
Han‐Yu Cao,
Si‐Man Huang,
Chong‐Sheng Qian,
Sheng‐Li Xue,
Hai‐Ping Dai,
Wen‐Jie Gong
Affiliations
Mei‐Jing Liu
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Kai‐Wen Tan
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Han‐Yu Cao
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Si‐Man Huang
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Chong‐Sheng Qian
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Sheng‐Li Xue
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Hai‐Ping Dai
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
Wen‐Jie Gong
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China
